

BGP-15 Inhibits Hyperglycemia-Aggravated VSMC Calcification Induced by High Phosphate

Annamária Nagy^{1,2#}, Dávid Pethő^{1,2#}, Rudolf Gesztelyi⁴, Béla Juhász⁴, György Balla^{3,5}, Zoltán Szilvássy⁴, József Balla^{1,*}, and Tamás Gáll^{1,3}

¹ Division of Nephrology, Department of Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary;

² Kálmán Laki Doctoral School, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary

³ HAS-UD Vascular Biology and Myocardial Pathophysiology Research Group, Hungarian Academy of Sciences, University of Debrecen, 4032 Debrecen, Hungary;


⁴ Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Debrecen, Nagyerdei krt 98., H-4032 Debrecen, Hungary

⁵ Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary

* Correspondence: balla@belklinika.com; Tel.: +36-52-255-500 / 55004

These authors contributed equally to this work.

A



B




Figure S1. Viability analysis of BGP-15-treated VSMCs. VSMCs were cultured in calcification medium containing 3 mmol/L inorganic Pi under normal glucose (5.5 mM glucose) and high glucose (11 mM) conditions in the presence or absence BGP-15 (15-100 μ M BGP-15 in NG and 25-200 μ M in HG condition) for 10 days. Cell viability was determined by MTT assay under normal glucose (A) and high glucose (HG) condition. Data are presented as mean \pm SEM of three independent experiments. Statistical analysis was performed by one-way ANOVA test followed by Bonferroni correction. A value of $p < 0.05$ was considered significant. *ns*: non-significant; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.